文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

治疗性单基因家族性高胆固醇血症与多基因高胆固醇血症患者的动脉粥样硬化更严重。

Greater preclinical atherosclerosis in treated monogenic familial hypercholesterolemia vs. polygenic hypercholesterolemia.

机构信息

Centre for Cardiovascular Genetics, University College London, The Rayne Institute, University Street, London, WC1E 6JF, UK; Department of Clinical Biochemistry, The Royal Free London NHS Foundation Trust, Pond Street, London, NW3 2QG, UK.

Department of Clinical Biochemistry, Russells Hall Hospital, The Dudley Group NHS Foundation Trust, West Midlands, DY1 2HQ, UK.

出版信息

Atherosclerosis. 2017 Aug;263:405-411. doi: 10.1016/j.atherosclerosis.2017.05.015. Epub 2017 May 13.


DOI:10.1016/j.atherosclerosis.2017.05.015
PMID:28549500
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5567405/
Abstract

BACKGROUND AND AIMS: Familial hypercholesterolemia (FH) is a common inherited disorder of low density lipoprotein-cholesterol (LDL-C) metabolism. It is associated with higher risk of premature coronary heart disease. Around 60% of patients with a clinical diagnosis of FH do not have a detectable mutation in the genes causing FH and are most likely to have a polygenic cause for their raised LDL-C. We assessed the degree of preclinical atherosclerosis in treated patients with monogenic FH versus polygenic hypercholesterolemia. METHODS: FH mutation testing and genotypes of six LDL-C-associated single nucleotide polymorphisms (SNPs) were determined using routine methods. Those with a detected mutation (monogenic) and mutation-negative patients with LDL-C SNP score in the top two quartiles (polygenic) were recruited. Carotid intima media thickness (IMT) was measured by B-mode ultrasound and the coronary artery calcium (CAC) score was performed in three lipid clinics in the UK and the Netherlands. RESULTS: 86 patients (56 monogenic FH, 30 polygenic) with carotid IMT measurement, and 166 patients (124 monogenic, 42 polygenic) with CAC score measurement were examined. After adjustment for age and gender, the mean of all the carotid IMT measurements and CAC scores were significantly greater in the monogenic than the polygenic patients [carotid IMT mean (95% CI): 0.74 mm (0.7-0.79) vs. 0.66 mm (0.61-0.72), p = 0.038 and CAC score mean (95%): 24.5 (14.4-41.8) vs. 2.65 (0.94-7.44), p = 0.0004]. CONCLUSIONS: In patients with a diagnosis of FH, those with a monogenic cause have a higher severity of carotid and coronary preclinical atherosclerosis than those with a polygenic aetiology.

摘要

背景与目的:家族性高胆固醇血症(FH)是一种常见的低密度脂蛋白胆固醇(LDL-C)代谢遗传疾病。它与冠心病的发生风险较高相关。约 60%的临床诊断为 FH 的患者并未检测到导致 FH 的基因突变,最有可能是由于多种基因导致 LDL-C 升高。我们评估了单基因突变 FH 患者与多基因突变高胆固醇血症患者的亚临床动脉粥样硬化程度。

方法:采用常规方法检测 FH 基因突变和 6 个 LDL-C 相关单核苷酸多态性(SNP)的基因型。选择检测到突变(单基因突变)的患者和 LDL-C SNP 评分在前两个四分位数(多基因突变)的突变阴性患者。采用 B 型超声测量颈动脉内膜中层厚度(IMT),并在英国和荷兰的 3 个血脂诊所进行冠状动脉钙评分(CAC)。

结果:共检查了 86 例(56 例单基因突变 FH,30 例多基因突变)有颈动脉 IMT 测量值的患者和 166 例(124 例单基因突变 FH,42 例多基因突变)有 CAC 评分测量值的患者。在调整年龄和性别后,单基因突变患者的所有颈动脉 IMT 测量值和 CAC 评分平均值均显著大于多基因突变患者[颈动脉 IMT 平均值(95%CI):0.74mm(0.7-0.79)与 0.66mm(0.61-0.72),p=0.038 和 CAC 评分平均值(95%):24.5(14.4-41.8)与 2.65(0.94-7.44),p=0.0004]。

结论:在 FH 诊断患者中,单基因突变病因患者的颈动脉和冠状动脉亚临床动脉粥样硬化程度比多基因突变病因患者更严重。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e1c4/5567405/f11e62822cba/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e1c4/5567405/4b602982dfe8/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e1c4/5567405/f11e62822cba/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e1c4/5567405/4b602982dfe8/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e1c4/5567405/f11e62822cba/gr2.jpg

相似文献

[1]
Greater preclinical atherosclerosis in treated monogenic familial hypercholesterolemia vs. polygenic hypercholesterolemia.

Atherosclerosis. 2017-5-13

[2]
Clinical Implications of Monogenic Versus Polygenic Hypercholesterolemia: Long-Term Response to Treatment, Coronary Atherosclerosis Burden, and Cardiovascular Events.

J Am Heart Assoc. 2021-5-4

[3]
Carotid artery plaques and intima medial thickness in familial hypercholesteraemic patients on long-term statin therapy: A case control study.

Atherosclerosis. 2017-1

[4]
Achilles tendon xanthomas are associated with the presence and burden of subclinical coronary atherosclerosis in heterozygous familial hypercholesterolemia: A pilot study.

Atherosclerosis. 2017-4-30

[5]
Evaluation of glycemic status and subclinical atherosclerosis in familial hypercholesterolemia subjects with or without LDL receptor mutation.

Cardiovasc Diabetol. 2025-3-20

[6]
Detecting familial hypercholesterolemia by serum lipid profile screening in a hospital setting: Clinical, genetic and atherosclerotic burden profile.

Nutr Metab Cardiovasc Dis. 2018-1

[7]
Factors Associated with Carotid Atherosclerosis and Achilles Tendon Thickness in Japanese Patients with Familial Hypercholesterolemia: A Subanalysis of the Familial Hypercholesterolemia Expert Forum (FAME) Study.

J Atheroscler Thromb. 2022-6-1

[8]
Polygenic Contribution to Low-Density Lipoprotein Cholesterol Levels and Cardiovascular Risk in Monogenic Familial Hypercholesterolemia.

Circ Genom Precis Med. 2020-10

[9]
Low-density lipoprotein levels and not mutation status predict intima-media thickness in familial hypercholesterolemia.

Ann Vasc Surg. 2014-2

[10]
Polygenic risk scores for low-density lipoprotein cholesterol and familial hypercholesterolemia.

J Hum Genet. 2021-11

引用本文的文献

[1]
Genetic Determinants of the Familial Hypercholesterolaemia Phenotype.

Ann Hum Genet. 2025-9

[2]
Clinical and biochemical features of atherogenic hyperlipidemias with different genetic basis: A comprehensive comparative study.

PLoS One. 2024-12-20

[3]
Familial Hypercholesterolemia: Pitfalls and Challenges in Diagnosis and Treatment.

Rev Cardiovasc Med. 2023-8-17

[4]
Aortic Wall Thickness as a Surrogate for Subclinical Atherosclerosis in Familial and Nonfamilial Hypercholesterolemia: Quantitative 3D Magnetic Resonance Imaging Study and Interrelations with Computed Tomography Calcium Scores, and Carotid Ultrasonography.

J Clin Med. 2023-8-27

[5]
Subclinical atherosclerosis determined by coronary artery calcium deposition in patients with clinical familial hypercholesterolemia.

Atheroscler Plus. 2022-11-11

[6]
Genetic and molecular architecture of familial hypercholesterolemia.

J Intern Med. 2023-2

[7]
The Clinical Importance of Differentiating Monogenic Familial Hypercholesterolemia from Polygenic Hypercholesterolemia.

Curr Cardiol Rep. 2022-11

[8]
Recent Advances on Familial Hypercholesterolemia in Children and Adolescents.

Biomedicines. 2022-4-30

[9]
Updates on the Use of Subclinical Atherosclerosis to Predict Risk of Cardiovascular Events in Heterozygous Familial Hypercholesterolemia.

Curr Atheroscler Rep. 2022-6

[10]
Twelve Variants Polygenic Score for Low-Density Lipoprotein Cholesterol Distribution in a Large Cohort of Patients With Clinically Diagnosed Familial Hypercholesterolemia With or Without Causative Mutations.

J Am Heart Assoc. 2022-4-5

本文引用的文献

[1]
Progression of coronary artery calcification at the crossroads: sign of progression or stabilization of coronary atherosclerosis?

Cardiovasc Diagn Ther. 2016-6

[2]
Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia.

J Am Coll Cardiol. 2016-6-7

[3]
Lipoprotein (a) levels are not associated with carotid plaques and carotid intima media thickness in statin-treated patients with familial hypercholesterolemia.

Atherosclerosis. 2015-9

[4]
Refinement of variant selection for the LDL cholesterol genetic risk score in the diagnosis of the polygenic form of clinical familial hypercholesterolemia and replication in samples from 6 countries.

Clin Chem. 2015-1

[5]
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society.

Eur Heart J. 2013-8-15

[6]
Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study.

Lancet. 2013-2-22

[7]
Carotid plaque burden as a measure of subclinical coronary artery disease in patients with heterozygous familial hypercholesterolemia.

Am J Cardiol. 2013-2-11

[8]
The effect of LDLR-negative genotype on CT coronary atherosclerosis in asymptomatic statin treated patients with heterozygous familial hypercholesterolemia.

Atherosclerosis. 2013-1-8

[9]
Coronary computed tomographic angiographic findings in asymptomatic patients with heterozygous familial hypercholesterolemia and null allele low-density lipoprotein receptor mutations.

Am J Cardiol. 2013-1-19

[10]
Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication.

J Clin Endocrinol Metab. 2012-8-14

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索